Cargando…

Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort

Triple‐negative breast cancer (TNBC) accounts for 15–20% of all newly diagnosed breast cancers, and is enriched for germline mutation of BRCA. In Asian patients diagnosed with breast cancer, 268 deleterious mutations of BRCA1 and 242 of BRCA2 have been identified so far, including a reported BRCA1 f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaoran, Li, Huiping, Shao, Bin, Wu, Jianmin, Kong, Weiyao, Song, Guohong, Jiang, Hanfang, Wang, Jing, Wan, Fengling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345662/ https://www.ncbi.nlm.nih.gov/pubmed/28135048 http://dx.doi.org/10.1002/cam4.1004

Ejemplares similares

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing
por: Wang, Nan, et al.
Publicado: (2020)

Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report
por: Gui, Xinyu, et al.
Publicado: (2018)

Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)
por: Jiang, Hanfang, et al.
Publicado: (2021)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
por: Litton, Jennifer K, et al.
Publicado: (2023)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Two activating mutations of MPL in triple‐negative myeloproliferative neoplasms
por: Xie, Juan, et al.
Publicado: (2019)

Outcomes and risk of subsequent breast events in breast‐conserving surgery patients with BRCA1 and BRCA2 mutation
por: Ye, Fugui, et al.
Publicado: (2020)

Expression and function of SLC38A5, an amino acid-coupled Na(+)/H(+) exchanger, in triple-negative breast cancer and its relevance to macropinocytosis
por: Ramachandran, Sabarish, et al.
Publicado: (2021)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers
por: Depypere, Herman, et al.
Publicado: (2021)

Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway
por: Xu, Yonggang, et al.
Publicado: (2021)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

BRCA1 and BRCA2 mutations and their clinical relevance in selected women diagnosed with triple-negative breast cancer in Kenya: a descriptive cross-sectional study
por: Rioki, Josephine Nyabeta, et al.
Publicado: (2023)

Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
por: Abd El-Aziz, Yomna S., et al.
Publicado: (2021)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status
por: Su, Ying-Wen, et al.
Publicado: (2018)

Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia
por: Wen, Wei Xiong, et al.
Publicado: (2018)

Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer
por: Ye, Fugui, et al.
Publicado: (2021)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
por: Savill, Kristin M Zimmerman, et al.
Publicado: (2023)

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014)

The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis
por: Zhang, Haomeng, et al.
Publicado: (2021)

Identification of tRNA‐derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple‐negative breast cancer
por: Feng, Wanting, et al.
Publicado: (2018)

Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer
por: Ferreira, Elisa Napolitano, et al.
Publicado: (2019)

The hedgehog pathway in triple‐negative breast cancer
por: Habib, Joyce G., et al.
Publicado: (2016)

Early‐onset triple‐negative breast cancer in multiracial/ethnic populations: Distinct trends of prevalence of truncation mutations
por: Liu, Qian, et al.
Publicado: (2019)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
por: Young, SR, et al.
Publicado: (2009)

Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia
por: PALOMBA, GRAZIA, et al.
Publicado: (2014)

Triple-negative Breast Cancer Arising in a Fibroadenoma in BRCA 1 Mutated Patient
por: Brunetti, Nicole, et al.
Publicado: (2022)

Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance
por: Anantha, Rachel W, et al.
Publicado: (2017)

Lamin B2 promotes the progression of triple negative breast cancer via mediating cell proliferation and apoptosis
por: Zhao, Cui-Cui, et al.
Publicado: (2021)

Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients
por: Singer, Christian F., et al.
Publicado: (2019)

Genetic evaluation of BRCA1-A complex genes with triple-negative breast cancer susceptibility in Chinese women
por: Ling, Hong, et al.
Publicado: (2016)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
por: Shao, Bin, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study
por: West, Allison H., et al.
Publicado: (2019)

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
por: Lips, E H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fpdkv8vgnh34ipdvdlimebelsi